Bio-Rad Laboratories Files 8-K with Bylaw & Exhibit Updates
Ticker: BIO-B · Form: 8-K · Filed: Sep 9, 2024 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: bylaws, exhibits, filing
Related Tickers: BIO
TL;DR
BIO-RAD files 8-K: Bylaw changes and exhibits updated. Nothing major, just housekeeping.
AI Summary
Bio-Rad Laboratories, Inc. filed an 8-K on September 9, 2024, reporting changes to its articles of incorporation or bylaws and filing financial statements and exhibits. The filing date for the report is September 6, 2024.
Why It Matters
This filing indicates potential administrative or structural changes within Bio-Rad Laboratories, Inc., which could affect its corporate governance or financial reporting.
Risk Assessment
Risk Level: low — The filing primarily concerns administrative updates and exhibit filings, with no immediate indication of significant financial or operational risks.
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — Registrant
- September 6, 2024 (date) — Earliest event reported date
- September 9, 2024 (date) — Filing date
- 1000 Alfred Nobel Dr. Hercules , California 94547 (address) — Principal executive offices
FAQ
What specific amendments were made to Bio-Rad Laboratories' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text of the 8-K.
What financial statements and exhibits are being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but the exact list or content of these documents is not detailed in the provided text.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated September 6, 2024.
What is Bio-Rad Laboratories, Inc.'s principal executive office address?
The principal executive offices are located at 1000 Alfred Nobel Dr. Hercules, California 94547.
What is the Commission File Number for Bio-Rad Laboratories, Inc.?
The Commission File Number for Bio-Rad Laboratories, Inc. is 1-7928.
Filing Stats: 660 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-09-09 16:30:32
Key Financial Figures
- $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Filing Documents
- bio-20240906.htm (8-K) — 35KB
- amendedandrestatedbylawsof.htm (EX-3.1) — 140KB
- redlineamendedandrestatedb.htm (EX-3.2) — 226KB
- 0000012208-24-000056.txt ( ) — 634KB
- bio-20240906.xsd (EX-101.SCH) — 3KB
- bio-20240906_def.xml (EX-101.DEF) — 16KB
- bio-20240906_lab.xml (EX-101.LAB) — 28KB
- bio-20240906_pre.xml (EX-101.PRE) — 16KB
- bio-20240906_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 6, 2024, the Board of Directors (the "Board") of Bio-Rad Laboratories, Inc. (the "Company") amended and restated the Company's amended and restated bylaws (the "Bylaws"), effective immediately, to (i) expressly provide for the ability of stockholders to participate in meetings of stockholders by electronic transmission, (ii) eliminate the requirement to make a stockholder list available for examination at meetings of stockholders, (iii) explicitly provide for the role of Chief Executive Officer, as separate from the role of President, (iv) require any stockholder directly or indirectly soliciting proxies from other stockholders to use a proxy card color other than white, (v) implement and update the procedure and information requirements for the nominations of persons for election to the Board, including to address matters relating to the new universal proxy rules set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as amended, or any proposal for other business; (vi) clarify the instances in which a stockholder's notice regarding nomination of a director for election or reelection or any proposal for other business may be disregarded and (vii) make certain other administrative, clarifying and conforming changes throughout. The foregoing summary is qualified in its entirety by reference to the complete text of the Bylaws, which are filed as Exhibit 3.1 hereto in unmarked form, and as Exhibit 3.2 hereto in redline form marking the amendments described above and are incorporated herein by reference.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits Exhibit Number Description 3.1 Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. effective September 6, 2024 3.2 Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. effective September 6, 2024 (redline) 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: September 9, 2024 By: /s/ Courtney C. Enloe Courtney C. Enloe Executive Vice President, General Counsel & Secretary